C.q. pharmaceutical holding (000950.SZ) announced that the net income for the first half of the year is expected to be between 220 million yuan and 260 million yuan, a decrease of 49.38%-57.17% compared with the same period last year. The non-net income is expected to be between 200 million yuan and 240 million yuan, a decrease of 49.33%-57.78% compared with the same period last year.
Following the '14th Five-Year Plan' strategy, the company continues to develop segmented businesses such as medical devices, traditional Chinese medicine health products, professional pharmacies, emerging businesses, and third-party reserves, while maintaining its main pharmaceutical business based on drug sales. Through internal development and external mergers and acquisitions, the company continuously improves its network layout. At the same time, the company attaches great importance to digital construction and research and development investment, and is committed to promoting and transforming to a modern pharmaceutical commerce that integrates 'Internet + medicine'. However, it faces the impact of tightening industry policies such as drug and equipment price adjustments due to the expansion of volume-based procurement of medicines and medical supplies, the comprehensive rollout of national and provincial centralized procurement, and alliance procurement.